Get started
Author

Hannah Sawyer

Observed name: Hannah R. Sawyer
Observed institution: Dana-Farber Cancer Institute
ORCID: 0009-0003-8591-3668
Observed ORCID: 0009-0003-8591-3668
OpenAlex ID: A5020540710
A Phase II, Two-Stage Study of Letrozole and Abemaciclib in Estrogen Receptor–Positive Recurrent Endometrial Cancer
2022 · Panagiotis A. Konstantinopoulos, Elizabeth K. Lee, et al. · Journal of Clinical Oncology · 91
Evaluation of Treatment With Talazoparib and Avelumab in Patients With Recurrent Mismatch Repair Proficient Endometrial Cancer
2022 · Panagiotis A. Konstantinopoulos, Allison A. Gockley, et al. · JAMA Oncology · 70
PDF
Combined PARP and HSP90 inhibition: preclinical and Phase 1 evaluation in patients with advanced solid tumours
2021 · Panagiotis A. Konstantinopoulos, Su-Chun Cheng, et al. · British Journal of Cancer · 38
Randomized Phase II Study of Gemcitabine With or Without ATR Inhibitor Berzosertib in Platinum-Resistant Ovarian Cancer: Final Overall Survival and Biomarker Analyses
2024 · Panagiotis A. Konstantinopoulos, Su-Chun Cheng, et al. · JCO Precision Oncology · 24
PDF
Abstract CT008: A phase 2, two-stage study of mirvetuximab soravtansine (IMGN853) in combination with pembrolizumab in patients with microsatellite stable (MSS) recurrent or persistent endometrial cancer
2024 · Rebecca L. Porter, Niya Xiong, et al. · Cancer Research · 16
A phase II trial of pembrolizumab and lenvatinib in recurrent or persistent clear cell ovarian carcinoma (NCT05296512).
2025 · Elizabeth Katherine Lee, Yinglu Zhou, et al. · Journal of Clinical Oncology · 10
Letrozole, abemaciclib and metformin in endometrial cancer: a non-randomized phase 2 trial
2025 · Panagiotis A. Konstantinopoulos, Ningxuan Zhou, et al. · Nature Communications · 8
PDF
Serial Circulating Tumor DNA Sequencing to Monitor Response and Define Acquired Resistance to Letrozole/Abemaciclib in Endometrial Cancer
2025 · Panagiotis A. Konstantinopoulos, Mingyang Cai, et al. · JCO Precision Oncology · 6
Randomized phase 2 study of gemcitabine with or without ATR inhibitor berzosertib in platinum-resistant ovarian cancer: Final overall survival (OS) and biomarker analyses.
2023 · Panagiotis A. Konstantinopoulos, Elizabeth Katherine Lee, et al. · Journal of Clinical Oncology · 6
PDF
Mirvetuximab soravtansine plus pembrolizumab in recurrent folate receptor alpha-positive uterine serous carcinoma: a phase II trial
2026 · Rebecca L. Porter, Yinglu Zhou, et al. · Nature Communications · 5
PDF
Phase 2 study of letrozole, abemaciclib, and metformin in estrogen receptor (ER)–positive recurrent endometrial cancer (EC).
2025 · Panagiotis A. Konstantinopoulos, Ningxuan Zhou, et al. · Journal of Clinical Oncology · 5
PDF
Combined aromatase, CDK4/6 and PI3K blockade using letrozole/abemaciclib/LY3023414 in endometrial cancer
2024 · Panagiotis A. Konstantinopoulos, Niya Xiong, et al. · Gynecologic Oncology Reports · 4
Phase 2, two-stage study of letrozole and abemaciclib in estrogen receptor (ER) positive recurrent or persistent endometrial cancer (072)
2022 · Panagiotis Konstantinopoulos, Elizabeth Lee, et al. · Gynecologic Oncology · 4
Phase 2 study of Wee1 inhibitor adavosertib in recurrent uterine carcinosarcoma
2025 · Stephanie Cham, Niya Xiong, et al. · Gynecologic Oncology Reports · 3
Phase 2, two-stage study of avelumab and axitinib in patients with mismatch repair proficient recurrent or persistent endometrial cancer
2025 · Elizabeth K. Lee, Niya Xiong, et al. · Gynecologic Oncology · 3
Abstract B041: A phase 1 study of DS-8201a in combination with olaparib in HER2-expressing malignancies (CTEP #10355): Results of module 1 dose escalation
2023 · Elizabeth K. Lee, Andrea E. Wahner Hendrickson, et al. · Molecular Cancer Therapeutics · 3
TP015/#1566 A phase 2, two-stage, study of mirvetuximab soravtansine (IMGN853) in combination with pembrolizumab in patients with microsatellite stable (MSS) recurrent or persistent endometrial cancer (EC)
2022 · Rebecca Porter, Nabihah Tayob, et al. · International Journal of Gynecological Cancer · 3
PDF
LB009/#1562 A phase II trial of pembrolizumab and lenvatinib in recurrent or persistent clear cell ovarian carcinoma (NCT05296512): stage 1 results
2024 · Elizabeth Lee, Yinglu Zhou, et al. · International Journal of Gynecological Cancer · 2
Phase II study of letrozole, abemaciclib and metformin in estrogen receptor-positive recurrent endometrial cancer
2025 · Panagiotis Konstantinopoulos, Ningxuan Zhou, et al. · Gynecologic Oncology · 1
Serial circulating tumor DNA (ctDNA) sequencing to monitor response and define acquired resistance to letrozole/abemaciclib in endometrial cancer (EC).
2024 · Panagiotis A. Konstantinopoulos, Mingyang Cai, et al. · Journal of Clinical Oncology · 1
Transcriptional signatures indicating RB function correlate with response to CDK4/6 inhibition in endometrial cancer
2026 · Zelei Yang, Upendra Raj Bhattarai, et al. · Clinical Cancer Research
Abstract CT035: CTEP #10355 A phase 1 trial of DS-8201a and olaparib in HER2-expressing malignancies: Results from dose escalation
2026 · Elizabeth K. Lee, Andrea Wahner Hendrickson, et al. · Cancer Research
Abstract 935: Co-clinical endometrial cancer (EC) patient-derived organoids (PDO) to assess functional effects of replication stress (RS)-targeting agents
2024 · Elena Ivanova, Aisha L. Saldanha, et al. · Cancer Research
Works count: 23
Citation count: 302
H-index: 7
I10-index: 6
Year
Topic
Type